3 best performing ASX shares in the week of 1 August 2022
Marc Kennis, August 8, 2022
Best performing ASX shares
The three best performing ASX shares in the week of 1 August 2022 were Plexure Group (ASX:PX1), up 97.1%, Resapp Health (ASX:RAP), up 65.2%, and Paradigm Biopharmaceuticals (ASX:PAR), up 52.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Plexure Group (ASX:PX1)
Industry: Software & IT Services
Plexure Group Limited (ASX:PX1) is a global mobile engagement company helping brands create sticky and more profitable relationships with consumers. Harnessing the power of consumer, contextual, behavioral and sales data, we enable the delivery of deeply personalized compelling offers to customers through mobile channels.
Market Cap: $118m
12 month high / low: $0.125 – $0.73

2. Resapp Health (ASX:RAP)
Industry: Technology
ResApp Health Limited (ASX:RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware.
Market Cap: $163M
12 month high / low: $0.042 – $0.1975
3. Paradigm Biopharmaceuticals (ASX:PAR)
Industry: Healthcare
Paradigm Biopharmaceuticals Limited (ASX:PAR) wraps our 3 best performing ASX shares this week. PAR is involved in researching and developing therapeutic products for human use. It is a drug repurposing company, which seeks to find new uses for old drugs, thereby reducing the cost and time to bring therapeutics to market.
Market Cap: $392m
12 month high / low: $0.855 – $2.69
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.

Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?
Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB)…
TechnologyOne (ASX: TNE) Wins $54.7M Legal Battle: Is the 34% Dip Now a Buying Opportunity?
TechnologyOne (ASX: TNE) has finally put one of Australia’s longest-running employment disputes behind it. The Federal Court threw out a…
Austal (ASX: ASB) Secures A$1bn Defence Win: A Defensive Buy at 28x Earnings?
Austal (ASX: ASB) locked in more than A$1.16 billion in new contracts last week, cementing its position as Australia’s go-to…